Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
The US Food and Drug Administration has granted Breakthrough Therapy designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have received prior taxane chemotherapy and androgen receptor (AR)-targeted therapy. 4 October 2019
Biotechnology
Arbutus Biopharma, a hepatitis B virus (HBV) therapeutic solutions company formerly called Tekmira, yesterday announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor. AB-506 was in a Phase Ia/Ib clinical trial for the treatment of chronic hepatitis B (CHB). 4 October 2019
Biotechnology
Karl Roberts, EY transactions advisory services managing director, shares an Expert View on individualized cell and gene therapies. 4 October 2019
Biotechnology
Following the failure of a key brain cancer study last month, Tocagen,a clinical-stage, US cancer-selective gene therapy company, on Thursday announced a restructuring to focus its resources on the clinical development of Toca 511 and Toca FC. 4 October 2019
Biotechnology
The US Food and Drug Administration has approved a pre-exposure prophylaxis (PrEP) indication for Gilead Sciences’ Descovy (emtricitabine/tenofovir alafenamide). 4 October 2019
Biotechnology
California, USA-based discovery start-up Tenaya Therapeutics today announced the successful completion of a $92 million Series B financing. 3 October 2019
Biotechnology
Goldfinch Bio, a US biotech developing precision medicines for kidney diseases, has agreed a licensing deal giving it global rights to a cannabinoid receptor 1 (CB1) monoclonal antibody from Japanese pharma major Takeda. 3 October 2019
Biotechnology
The Japanese Intellectual Property High Court has ruled in favor of the Roche majority-owned subsidiary Chugai in relation to allegations that its hemophilia A drug Hemlibra (emicizumab-kxwh) breached another company’s patent. 3 October 2019
Biotechnology
Following a second piece of good news this week, Heron Therapeutics’ market capitalization hit $1.49 billion yesterday. 3 October 2019
Biotechnology
Following the news that the US Food and Drug Administration had approved a labeling supplement for Nerlynx (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer, shares of Puma Biotech shot up 13% in after-hours trading on Wednesday. 3 October 2019
Biotechnology
A report from the UK BioIndustry Association (BIA) finds that investment in UK biotech companies is slowing, with a total of £869 million ($1 billion) being raised for the year up to 31 August. 2 October 2019
Biotechnology
US biotech Q BioMed saw its share rise 8.3% to $0.46 in early trading, after the company revealed it has entered into a settlement agreement with BioNucleonics to complete the outright acquisition of the non-opioid cancer bone pain drug Strontium-89 Chloride USP. 2 October 2019
Biotechnology
Japanese drug major Shionogi has announced positive results from the Phase III APEKS-NP study of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP). 2 October 2019
Biotechnology
Swedish startup Lobsor Pharmaceuticals expects to complete registration in the Nordic region for its lightweight Parkinson’s disease therapy Lecigon (levodopa/carbidopa/entacapone) this month. 2 October 2019
Biotechnology
Keytruda (pembrolizumab) has been approved in China for first-line treatment of certain patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1. 2 October 2019
Biotechnology
Health Sciences Acquisitions Corp and Immunovant Sciences, a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases and a member of Switzerland's Roivant family of companies, today announced that they have entered into a definitive share exchange agreement (SEA). 2 October 2019
Biotechnology
Japanese drugmaker Asahi Kasei Pharma has filed a complaint requesting a preliminary injunction against Endo Ventures Limited and Endo Pharmaceuticals to require Ireland-incorporated Endo to continue to supply the company with Xiaflex (collagenase clostridium histolyticum), for the treatment of Dupuytren’s contracture. 2 October 2019
Biotechnology
Tridek-One, a privately-held French biotech specializing in the development of products for the treatment of immune and inflammatory disorders, has named three new members of its executive team. 2 October 2019
Biotechnology
Swiss pharma giant Novartis has presented additional data from the Phase III PREVENT trial on the use of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis (nr-axSpA). 2 October 2019
Biotechnology
Cambridge, USA-based cell and gene therapy specialist ElevateBio has launched a new company, dubbed HighPassBio, dedicated to advancing novel T cell immunotherapies. 1 October 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze